|
|
|
Volumn 3, Issue 11, 2005, Pages 832-834
|
|
New agents in the treatment of MDS
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 AZA 2' DEOXYCYTIDINE;
ANTINEOPLASTIC AGENT;
ARSENIC TRIOXIDE;
AZACITIDINE;
BEVACIZUMAB;
DNA METHYLTRANSFERASE;
ERYTHROPOIETIN;
ERYTHROPOIETIN RECEPTOR;
GLUTATHIONE TRANSFERASE;
GRANULOCYTE COLONY STIMULATING FACTOR;
IRON CHELATING AGENT;
LENALIDOMIDE;
MITOGEN ACTIVATED PROTEIN KINASE P38;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
RECOMBINANT ERYTHROPOIETIN;
SCIO 469;
STAT5 PROTEIN;
STRESS ACTIVATED PROTEIN KINASE;
TELINTRA;
THALIDOMIDE;
TLK 199;
TUMOR NECROSIS FACTOR;
UNCLASSIFIED DRUG;
VASCULOTROPIN;
VASCULOTROPIN RECEPTOR;
ACUTE GRANULOCYTIC LEUKEMIA;
ANGIOGENESIS;
ANTINEOPLASTIC ACTIVITY;
BLOOD TRANSFUSION;
CANCER RISK;
CANCER SURVIVAL;
CELLULAR IMMUNITY;
CHROMOSOME 5Q;
CHROMOSOME DELETION;
CLINICAL TRIAL;
CYTOTOXICITY;
DOSE RESPONSE;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG INDICATION;
DRUG MECHANISM;
DRUG TARGETING;
FOLLOW UP;
FOOD AND DRUG ADMINISTRATION;
HIGH RISK PATIENT;
HUMAN;
IMMUNOMODULATION;
IN VITRO STUDY;
KARYOTYPE;
LEUKEMIA REMISSION;
MEDICAL SOCIETY;
MYELODYSPLASTIC SYNDROME;
NOTE;
RISK ASSESSMENT;
TREATMENT INDICATION;
ANGIOGENESIS INHIBITORS;
ANTIMETABOLITES, ANTINEOPLASTIC;
AZACITIDINE;
CLINICAL TRIALS, PHASE III;
ENZYME INHIBITORS;
HUMANS;
INDOLES;
MYELODYSPLASTIC SYNDROMES;
PREDICTIVE VALUE OF TESTS;
THALIDOMIDE;
TREATMENT OUTCOME;
|
|
EID: 29744452397
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (6)
|
|
References (4)
|
